Friedreich Ataxia and close related scientific news. Topics related to rare diseases.
Tuesday, March 10, 2026
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
March 09, 2026 16:01 ET | Source: Voyager Therapeutics, Inc..
Neurocrine partnership update: Neurocrine has stated that, pending successful FDA IND clearance, it intends to initiate a clinical trial with NBIB-‘223 for Friedreich’s ataxia in H2 2026.